Nurix Therapeutics (NRIX) Change in Accured Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Change in Accured Expenses for 8 consecutive years, with -$15.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 117.71% year-over-year to -$15.3 million; the TTM figure through May 2026 stood at $6.2 million (down 58.36% YoY), while the FY2025 annual figure was $17.3 million, up 46.5% from the prior year.
• Change in Accured Expenses eased to -$15.3 million in Q2 2026 per NRIX's latest filing, from $4.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $11.0 million in Q4 2025 and bottomed at -$15.3 million in Q2 2026.
• Historically, Change in Accured Expenses has averaged $1.6 million across 5 years, with a median of $3.4 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 314.68% — and 2024, when it tumbled 402.88%.
• Nurix Therapeutics' Change in Accured Expenses stood at $3.3 million in 2022, then declined by 6.71% to $3.1 million in 2023, then soared by 193.46% to $9.0 million in 2024, then advanced by 22.36% to $11.0 million in 2025, then tumbled by 238.14% to -$15.3 million in 2026.
• Business Quant data shows NRIX's Change in Accured Expenses at -$15.3 million in Q2 2026, $4.1 million in Q1 2026, and $11.0 million in Q4 2025.